Source: Annual Congress 2013 –New drugs in respiratory medicine



Rating:

Share or cite this content

Citations should be made in the following way:
I. Pavord, A. De Soyza, J. S. Elborn, D. Smith, H. Wray, M. Puu, B. Larsson, R. Stockley (Leicester, Newcastle upon Tyne, Belfast, Bristol, Birmingham, United Kingdom; Mölndal, Sweden). Efficacy and safety of AZD5069, a CXCR2 antagonist, in adult bronchiectasis. Eur Respir J 2013; 42: Suppl. 57, 1593

Member's Comments

Evelina Lokshina (Chernogolovka, Russian Federatio - 11.09.2013 11:08
Deae Giancarlo! Thank you for very intresting work. I would like to know more about your study. What infections did you study?

Related content which might interest you: The in vitro profile of ADC3680, a potent and selective CRTh2 antagonist for the treatment of inadequately controlled asthma Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 AZD5069: Pharmacological profile of a CXCR2 antagonist in development for the treatment of respiratory disorders Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Effect of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of AZD5069, an oral CXCR2 antagonist Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 An open-label pilot study of memantine, an N-methyl-D-aspartate receptor antagonist in chronic cough Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Efficacy and safety of abediterol, a long-acting beta2-adrenergic agonist (LABA); three phase II trials in asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Pharmacological treatment of asthma today Source: Eur Respir J 2001; 18: 34S-40S Year: 2001 The inverse agonist propranolol does not confer steroid-sparing activity in persistent asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 In vitro profile of the new inhaled pan-JAK inhibitor LAS194046 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Safety, tolerability and pharmacokinetics of CHF 6001, a novel selective inhaled PDE4 inhibitor, in healthy volunteers Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016 Safety and efficacy of SCH527123, a novel CXCR2 antagonist, in patients with COPD Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease Year: 2010 In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Decoy chemokine neutraligands with anti-asthmatic activity Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 The safety, PK and PD profile of ADC3680, a potent and selective CRTh2 antagonist, in healthy volunteers and partly controlled atopic asthmatic subjects Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Safety and tolerability of the NE inhibitor BAY 85-8501 in patients with non-CF bronchiectasis Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016 Safety, tolerability and pharmacokinetics of an oral competitive reversible CRTh2 antagonist, QAW039, in healthy subjects Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 LATE-BREAKING ABSTRACT: Safety, pharmacokinetics and pharmacodynamics of BI 1060469, a novel oral CRTH2 antagonist Source: International Congress 2016 – Asthma management Year: 2016 Safety, tolerability and pharmacokinetics of QAV680, an oral CRTh2 antagonist, in healthy subjects Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Side effects of the leukotriene receptor antagonists in asthmatic children Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014